Anti-TNF-alpha Chimeric Mouse-Human (Clone D2E7)

TNF-alpha is a cytokine and a member of the TNF/TNF receptor (TNFR) cytokine superfamily. TNF-alpha is produced as a 233-amino acid transmembrane precursor protein from which mature, soluble TNF-alpha is formed by proteolysis. Soluble TNF-alpha is a 157-amino acid polypeptide, cleaved from the precursor protein on the extracellular side of the membrane, that forms bell-shaped homotrimers with the C-termini at the base, each containing three receptor interaction sites. It is primarily produced by activated macrophages but can also be produced by a variety of other cells, such as T cells, natural killer cells, and osteoblasts. TNF-alpha binds to and activates its receptors, TNFR1 and TNFR2, which are associated with intracellular protein complexes that activate caspases to induce cell death, induce p38 MAPK signaling, and initiate NF-kappaB or AP-1-mediated transcription of immune and inflammatory mediators. TNF-alpha promotes inflammation partly by inducing endothelial cells to express adhesion molecules, COX enzymes, and pro-coagulant factors. Exogenous TNF-alpha induces death of cancer cells in vitro, as well as disrupts tumor vascularization and induces tumor necrosis in vivo, but it has tumor-promoting properties when produced in the cancer microenvironment. In contrast, it plays a role in resistance to infection, with mice lacking Tnf having an increased susceptibility to certain microbial infections but lacking resistance to leishmania. Tnf knockout mice are also resistant to certain types of cancer, including chemically induced skin carcinogenesis. TNF-alpha increases lung metastases in a mouse model of fibrosarcoma, an effect that can be reduced by an anti-TNF-alpha antibody. Mice overexpressing Tnf develop an arthritis similar to rheumatoid arthritis in humans. TNF-alpha is produced in the inflamed tissues of patients with inflammatory diseases such as rheumatoid arthritis, and neutralizing antibodies to TNF-alpha reduce the levels of TNF-alpha in vitro and in mouse models of the disease. Cayman's TNF-alpha Chimeric Mouse-Human Monoclonal Antibody (Clone D2E7) was produced recombinantly from the original D2E7 antibody sequence and can be used for ELISA, immunofluorescence (IF), and immunohistochemistry (IHC) applications. The D2E7 antibody was generated by affinity maturation from the 2SD4 scFv, which, in turn, was selected on human TNF-alpha by guided phage-display technology using the mouse anti-hTNF-alpha antibody Mab32 as a template.Synonyms: DIF, Differentiation-inducing Factor, TNFA, TNFSF2, Tumor Necrosis Factor-alpha. Immunogen: Human TNF-alpha. Clone Designation: D2E7 (Adalimumab). Formulation: (Request formulation change), 200 µg of protein A-affinity purified monoclonal antibody. Storage Buffer: PBS with 0.02% ProClin(TM) 300. Host: Chimeric Monoclonal Antibody. Isotype: Human IgG1kappa. Applications: ELISA, IF, IHC. Cross Reactivity: (+) TNF-alpha, (+) Soluble TNF-alpha, (-) TNF-beta. UniProt Accession #: P01375.